Foxconn was among the investors in a $35m second tranche of a round also backed by Aviva Ventures which now stands at $50m.
Owlstone Medical, the UK-based creator of a lung disease diagnostics device, has closed its latest funding round at $50m after raising $35m from investors including manufacturing services provider Foxconn.
Venture capital firm Horizons Ventures led the second tranche, which included investment firm Ventura Capital. It followed a $15m first close co-led by Horizons Ventures and Aviva Ventures, the strategic investment arm of insurance firm Aviva, in March this year.
Spun out of chemical detection technology provider Owlstone in 2016,…
